Document Detail

Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.
MedLine Citation:
PMID:  15187246     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To determine the safety and therapeutic response of a regimen consisting of cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) plus rituximab in patients with Sjögren's syndrome (SS) and aggressive non-Hodgkin's lymphoma (NHL). METHODS: Four SS patients with aggressive marginal zone NHL were enrolled in this trial. All patients were classified according to the newly proposed revised European-American classification of lymphoid neoplasms. Three out of four patients also had mixed cryoglobulinaemia (MC) of type II. They were treated every 3 weeks for eight cycles of CHOP. Patients also received rituximab, at a dose of 375 mg per square metre, on day 1 of each of the eight cycles of CHOP. Four weeks after completion of the eighth course of CHOP plus rituximab and every 6 months thereafter, patients were re-evaluated for response. RESULTS: Complete remission of lymphoma was achieved in all four patients. The lymphoma patients remained in remission for a period of 23, 15, 12 and 10 months respectively, while certain signs and symptoms of MC type II (purpura, peripheral neuropathy and arthralgias) significantly improved with treatment. In addition, the titres of circulating cryoglobulins and RF decreased, while C4 levels returned to normal. CONCLUSION: CHOP plus rituximab was well tolerated and proved effective in SS patients with aggressive NHL. Our observations may warrant a larger controlled trial to assess the effectiveness of this regimen in such patients.
M Voulgarelis; S Giannouli; D Anagnostou; A G Tzioufas
Related Documents :
7074646 - Posttreatment laparotomy as a guide to management in patients with hodgkin's disease.
1694156 - Risk of infertility in patients with hodgkin's disease treated with abvd vs mopp vs abv...
282856 - Retroperitoneal fibrosis, methysergide and malignant lymphoma.
944086 - Idiopathic thrombocytopenic purpura in lymphoma.
2599836 - Warts in general practice.
25187906 - Oral treprostinil for the treatment of pulmonary arterial hypertension.
Publication Detail:
Type:  Journal Article     Date:  2004-06-08
Journal Detail:
Title:  Rheumatology (Oxford, England)     Volume:  43     ISSN:  1462-0324     ISO Abbreviation:  Rheumatology (Oxford)     Publication Date:  2004 Aug 
Date Detail:
Created Date:  2004-07-19     Completed Date:  2004-08-30     Revised Date:  2007-09-06    
Medline Journal Info:
Nlm Unique ID:  100883501     Medline TA:  Rheumatology (Oxford)     Country:  England    
Other Details:
Languages:  eng     Pagination:  1050-3     Citation Subset:  AIM; IM    
Department of Pathophysiology, Medical School, National University of Athens, M. Asias 75, Goudi, 11527, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / adverse effects,  therapeutic use*
Antigens, CD / analysis
Antineoplastic Agents / adverse effects,  therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use*
B-Lymphocytes / immunology
Cryoglobulinemia / etiology
Cyclophosphamide / adverse effects,  therapeutic use*
Doxorubicin / adverse effects,  therapeutic use*
Drug Therapy, Combination
Lymphoma, B-Cell / drug therapy*,  etiology
Middle Aged
Prednisone / adverse effects,  therapeutic use*
Sjogren's Syndrome / complications*
Treatment Outcome
Vincristine / adverse effects,  therapeutic use*
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antigens, CD; 0/Antineoplastic Agents; 0/CHOP protocol; 0/rituximab; 23214-92-8/Doxorubicin; 50-18-0/Cyclophosphamide; 53-03-2/Prednisone; 57-22-7/Vincristine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  More 'cries from the joints': assessment of the musculoskeletal system is poorly documented in routi...
Next Document:  G1 and S-phase checkpoints, chromosome instability, and cancer.